CMMB vs. JSPR, IGMS, MNOV, CNTX, INCR, ANL, MCRB, BYSI, VTVT, and UNCY
Should you be buying Chemomab Therapeutics stock or one of its competitors? The main competitors of Chemomab Therapeutics include Jasper Therapeutics (JSPR), IGM Biosciences (IGMS), MediciNova (MNOV), Context Therapeutics (CNTX), InterCure (INCR), Adlai Nortye (ANL), Seres Therapeutics (MCRB), BeyondSpring (BYSI), vTv Therapeutics (VTVT), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry.
Chemomab Therapeutics vs.
Chemomab Therapeutics (NASDAQ:CMMB) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, community ranking, dividends, institutional ownership, analyst recommendations, earnings and valuation.
In the previous week, Jasper Therapeutics had 10 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 16 mentions for Jasper Therapeutics and 6 mentions for Chemomab Therapeutics. Chemomab Therapeutics' average media sentiment score of 0.22 beat Jasper Therapeutics' score of -0.01 indicating that Chemomab Therapeutics is being referred to more favorably in the media.
Chemomab Therapeutics currently has a consensus price target of $8.50, indicating a potential upside of 515.94%. Jasper Therapeutics has a consensus price target of $62.22, indicating a potential upside of 1,190.92%. Given Jasper Therapeutics' higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than Chemomab Therapeutics.
Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Jasper Therapeutics, indicating that it is currently the more affordable of the two stocks.
Jasper Therapeutics' return on equity of -67.64% beat Chemomab Therapeutics' return on equity.
Chemomab Therapeutics has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.74, suggesting that its stock price is 174% more volatile than the S&P 500.
Jasper Therapeutics received 28 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 90.57% of users gave Jasper Therapeutics an outperform vote while only 66.67% of users gave Chemomab Therapeutics an outperform vote.
46.0% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 79.8% of Jasper Therapeutics shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Jasper Therapeutics beats Chemomab Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Chemomab Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CMMB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Chemomab Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:CMMB) was last updated on 5/22/2025 by MarketBeat.com Staff
